MicroRNA-21: A promising biomarker for the prognosis and diagnosis of non-small cell lung cancer

Oncol Lett. 2018 Sep;16(3):2777-2782. doi: 10.3892/ol.2018.8972. Epub 2018 Jun 15.

Abstract

Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer worldwide. The high mortality rate of NSCLC is due to a limited number of diagnosis being made at an early stage of disease. Therefore, the development of a novel biological marker for the diagnosis and prognosis prediction of NSCLC remains urgent. Current literature shows that microRNA-21 (miRNA-21/miR-21), as an oncogenic miRNA, is involved in the growth, metastasis and apoptosis of NSCLC cells through its control of various target molecules and signaling pathways. Notably, a growing body of evidence further shows that miR-21 is closely associated with the prognosis prediction, recurrence and diagnosis of cancer patients, indicating that miR-21 may be a novel promising biomarker for the diagnosis and prognosis prediction of NSCLC. The present review aimed to provide a summary of recent findings on the associated progression toward finding a novel biomarker for NSCLC.

Keywords: diagnosis; metastasis; microRNA-21; non-small cell lung cancer; prognosis.

Publication types

  • Review